Clinical Trial Update: Circulating Tumor DNA (ctDNA) as a Predictive Biomarker for Immunotherapy in Advanced or Locally Advanced dMMR/MSI-H Colorectal Patients

View source ↗

Summary

This clinical trial update evaluates circulating tumor DNA as a predictive biomarker for immunotherapy in advanced or locally advanced dMMR/MSI-H colorectal can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Snippet

Sponsor: Geneplus-Beijing Co. Ltd. | Conditions: Colorectal Cancer | Status: RECRUITING